Stony Brook study links PTSD in WTC responders to accelerated biological aging

Stony Brook University researchers say PTSD in World Trade Center responders was associated with molecular signs of accelerated biological aging decades after the Sept. 11 attacks.

The study was reported June 30 and cited as published in Nature Communications. It looked at blood samples from 393 responders enrolled in the Stony Brook WTC Wellness Program, including 232 who were diagnosed with PTSD and 161 who were not.

Researchers collected the samples about 18 years after 9/11 and compared protein and metabolite patterns between the two groups. They said the analysis identified significant differences in 114 proteins and 7 metabolites.

What the study examined

The reported molecular changes were tied to brain function, immune activity, energy metabolism, cell repair, and protection against cell damage. The researchers also said the patterns pointed to accelerated biological aging in multiple organs, including the heart, kidneys, liver, and lungs.

Benjamin Luft, the lead study author and principal investigator at the Stony Brook WTC Wellness Program, was identified as the study's lead author. The findings add a biological dimension to long-running questions about the long-term health effects of trauma on first responders.

The study focuses on association, not causation. That means the reported results do not prove PTSD caused the molecular changes linked to aging, only that the two were connected in this sample.

Public-health context

The World Trade Center Health Program, administered by the CDC through NIOSH, provides medical monitoring and treatment for eligible 9/11 responders and survivors. PTSD is already a covered WTC Health Program condition, reflecting the broader health burden tied to the attacks.

That context makes the study relevant for long-term care planning. If PTSD is associated with biological aging signals in aging responders, clinicians and public-health officials may want to watch more closely for chronic disease risk in this population.

The reported sample size is substantial, but the evidence still has limits. This was a biomarker study rather than a clinical trial, and the research as reported does not establish how directly the molecular findings translate into disease outcomes for individual patients.

What happens next

The open questions now are whether Stony Brook or the journal will publish fuller methodological detail and whether independent researchers will weigh in on the strength of the biomarker signal.

The study also raises a practical question for trauma care: how findings like these should shape long-term monitoring for first responders and other survivors exposed to major traumatic events.

For now, the research adds a new layer to the health legacy of 9/11. In the responders studied, PTSD was linked not only to mental-health burden, but also to measurable signs of aging across the body.